{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02605421",
            "orgStudyIdInfo": {
                "id": "2015LS108"
            },
            "organization": {
                "fullName": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma",
            "officialTitle": "Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "myeloablative-consolidation-therapy-and-tandem-autologous-stem-cell-rescue-in-patients-with-high-risk-neuroblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2015-11-12",
            "studyFirstSubmitQcDate": "2015-11-12",
            "studyFirstPostDateStruct": {
                "date": "2015-11-16",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the start of Induction Cycle #5."
        },
        "conditionsModule": {
            "conditions": [
                "Neuroblastoma"
            ],
            "keywords": [
                "High-risk neuroblastoma",
                "Neuroblastoma",
                "Myeloablative chemotherapy",
                "Myeloablative consolidation chemotherapy",
                "Autologous peripheral blood stem cell rescue",
                "PBSC",
                "Autologous stem cell rescue"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Patients Treated for Neuroblastoma",
                    "type": "EXPERIMENTAL",
                    "description": "Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.",
                    "interventionNames": [
                        "Drug: Thiotepa",
                        "Drug: Cyclophosphamide",
                        "Drug: Melphalan",
                        "Drug: Etoposide",
                        "Drug: Carboplatin",
                        "Biological: Autologous Stem Cell Infusion",
                        "Biological: Granulocyte colony stimulating factor"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Thiotepa",
                    "description": "Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Melphalan",
                    "description": "Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Etoposide",
                    "description": "Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Autologous Stem Cell Infusion",
                    "description": "On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Granulocyte colony stimulating factor",
                    "description": "Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \\> 2000/\u03bcL for 3 consecutive days.",
                    "armGroupLabels": [
                        "Patients Treated for Neuroblastoma"
                    ],
                    "otherNames": [
                        "G-CSF"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression Free Survival",
                    "description": "Percentage of patients with progression free survial. Kaplan-Meier curves and 95% confidence intervals will be used to estimate.",
                    "timeFrame": "3 years from first PBSC infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to Engraftment",
                    "description": "Defined as an absolute neutrophil count (ANC) greater than or equal to 0.5 x 109/L for three consecutive days by day 42 after first transplant.",
                    "timeFrame": "Day 42"
                },
                {
                    "measure": "Relapse",
                    "description": "Percentage of patients with relapse. Relapse will be defined as any new lesion; increase of any measurable lesion by \\>25%; previous negative bone is positive.",
                    "timeFrame": "3 years from first PBSC infusion"
                },
                {
                    "measure": "Overall Survival",
                    "description": "Kaplan-Meier curves and 95% confidence intervals will be used to estimate overall survival.",
                    "timeFrame": "3 years from first PBSC infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "* Less than 30 years of age at diagnosis of neuroblastoma\n* End of Induction disease evaluation demonstrating CR, PR, MR or SD\n* Hematopoietic Recovery from last induction course of chemotherapy\n* No uncontrolled infection\n* Minimum frozen PBSCs of 2 x 10\\^6 CD34 cells/kg for each transplant are mandatory and a PBSC of 2 x 10\\^6 CD34 cells/kg for back-up are strongly recommended (thus, PBSC of no less than 6 x 10\\^6 CD34 cells/kg is encouraged). These must all be collected prior to the initiation of consolidation.\n* Adequate organ function defined as:\n\n  * Hepatic: AST and ALT \\< 3 x upper limit of institutional normal; ALT \u2264 3 x ULN for age; total bilirubin \u2264 1.5 x ULN for age, if baseline was normal, \\> 1.0 1.5 x baseline if baseline was abnormal\n  * Cardiac: shortening fraction \u2265 27% or ejection fraction \u2265 45%, no clinical congestive heart failure\n  * Pulmonary: no evidence of dyspnea at rest and norequirement for supplemental oxygen\n  * Renal: Creatinine clearance or GFR \\> 60 mL/min/1.73m\\^2. If a creatinine clearance is performed at end induction and the result is \\< 100 ml/min/1.73m\\^2, a GFR must then be performed using a nuclear blood sampling method or iothalamate clearance method. Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of \\< 100 ml/min/1.73m\\^2\n* Recovery from acute toxicities of last cycle of induction chemotherapy\n* Appropriate written consent - adult or parent/guardian if patient is \\< 18 years of age and minor information sheet if patient is \\> 8 years of age",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "30 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lisa Burke",
                    "role": "CONTACT",
                    "phone": "612-273-8482",
                    "email": "lburke3@Fairview.org"
                },
                {
                    "name": "Ashish Gupta, MBBS, MPH",
                    "role": "CONTACT",
                    "phone": "612-626-2961",
                    "email": "stef0030@umn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ashish Gupta, MBBS, MPH",
                    "affiliation": "Masonic Cancer Center, University of Minnesota",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Masonic Cancer Center, University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Burke, RN",
                            "role": "CONTACT",
                            "phone": "612-273-8482",
                            "email": "lburke3@Fairview.org"
                        },
                        {
                            "name": "Ashish Gupta, MBBS, MPH",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009447",
                    "term": "Neuroblastoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018241",
                    "term": "Neuroectodermal Tumors, Primitive, Peripheral"
                },
                {
                    "id": "D000018242",
                    "term": "Neuroectodermal Tumors, Primitive"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12391",
                    "name": "Neuroblastoma",
                    "asFound": "Neuroblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20387",
                    "name": "Neuroectodermal Tumors, Primitive, Peripheral",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T4085",
                    "name": "Neuroblastoma",
                    "asFound": "Neuroblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000008558",
                    "term": "Melphalan"
                },
                {
                    "id": "D000013852",
                    "term": "Thiotepa"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "D000005047",
                    "term": "Etoposide"
                },
                {
                    "id": "D000078224",
                    "term": "Lenograstim"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000276",
                    "term": "Adjuvants, Immunologic"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8191",
                    "name": "Etoposide",
                    "asFound": "Complete",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11541",
                    "name": "Melphalan",
                    "asFound": "Controlled Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1945",
                    "name": "Lenograstim",
                    "asFound": "mA",
                    "relevance": "HIGH"
                },
                {
                    "id": "M341643",
                    "name": "Etoposide phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M16615",
                    "name": "Thiotepa",
                    "asFound": "Tear",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M3628",
                    "name": "Adjuvants, Immunologic",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}